Sonoma Pharmaceuticals (SNOA) Competitors $3.61 -0.33 (-8.38%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$3.78 +0.17 (+4.57%) As of 07/11/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNOA vs. BIVI, CGTX, JATT, QTTB, LPCN, CING, MTEX, GELS, CARM, and MRKRShould you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include BioVie (BIVI), Cognition Therapeutics (CGTX), JATT Acquisition (JATT), Q32 Bio (QTTB), Lipocine (LPCN), Cingulate (CING), Mannatech (MTEX), Gelteq (GELS), Carisma Therapeutics (CARM), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical products" industry. Sonoma Pharmaceuticals vs. Its Competitors BioVie Cognition Therapeutics JATT Acquisition Q32 Bio Lipocine Cingulate Mannatech Gelteq Carisma Therapeutics Marker Therapeutics Sonoma Pharmaceuticals (NASDAQ:SNOA) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends. Does the media favor SNOA or BIVI? In the previous week, Sonoma Pharmaceuticals and Sonoma Pharmaceuticals both had 2 articles in the media. BioVie's average media sentiment score of 1.93 beat Sonoma Pharmaceuticals' score of 0.94 indicating that BioVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sonoma Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioVie 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is SNOA or BIVI more profitable? BioVie has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -24.23%. Sonoma Pharmaceuticals' return on equity of -58.73% beat BioVie's return on equity.Company Net Margins Return on Equity Return on Assets Sonoma Pharmaceuticals-24.23% -58.73% -21.05% BioVie N/A -100.88%-78.49% Do insiders & institutionals believe in SNOA or BIVI? 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 4.6% of BioVie shares are held by institutional investors. 3.9% of Sonoma Pharmaceuticals shares are held by insiders. Comparatively, 2.4% of BioVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk and volatility, SNOA or BIVI? Sonoma Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, BioVie has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Do analysts prefer SNOA or BIVI? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BioVie 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Which has higher earnings & valuation, SNOA or BIVI? Sonoma Pharmaceuticals has higher revenue and earnings than BioVie. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSonoma Pharmaceuticals$14.29M0.41-$3.46M-$3.10-1.16BioVieN/AN/A-$32.12M-$79.10-0.09 SummarySonoma Pharmaceuticals beats BioVie on 7 of the 13 factors compared between the two stocks. Get Sonoma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNOA vs. The Competition Export to ExcelMetricSonoma PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.47M$2.74B$5.62B$9.10BDividend YieldN/A1.79%5.24%4.00%P/E Ratio-1.169.4228.1320.27Price / Sales0.41714.13428.6398.72Price / CashN/A165.3637.4658.16Price / Book1.324.608.045.49Net Income-$3.46M$31.26M$3.18B$250.45M7 Day Performance21.14%4.80%3.62%4.78%1 Month Performance14.24%5.42%4.05%7.67%1 Year Performance871.74%-4.36%30.00%16.43% Sonoma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNOASonoma Pharmaceuticals0.7337 of 5 stars$3.61-8.4%N/A+917.2%$6.47M$14.29M-1.16180Gap UpBIVIBioVie1.1399 of 5 stars$0.93-8.4%N/A+63.7%$18.76MN/A-0.1210News CoveragePositive NewsCGTXCognition Therapeutics2.9539 of 5 stars$0.31+3.3%$5.63+1,715.7%-69.0%$18.60MN/A-0.4220News CoverageAnalyst DowngradeGap DownJATTJATT AcquisitionN/A$1.05-8.7%N/A-61.9%$18.11MN/A0.003High Trading VolumeQTTBQ32 Bio2.7107 of 5 stars$1.49+2.8%$12.17+716.6%-88.1%$17.69M$1.16M-0.3039Gap DownLPCNLipocine2.564 of 5 stars$3.16-4.0%$9.00+184.8%-57.4%$17.60M$11.20M-3.1010CINGCingulate3.1081 of 5 stars$4.07+0.5%$26.00+538.8%+805.5%$17.19MN/A-0.4820News CoverageMTEXMannatech1.4052 of 5 stars$9.35+3.9%N/A+20.4%$17.11M$117.87M-93.50250High Trading VolumeGELSGelteqN/A$1.73-4.4%N/AN/A$17.08M$100K0.00N/AGap DownCARMCarisma Therapeutics3.1494 of 5 stars$0.39-2.2%$1.93+391.6%-66.7%$16.74M$19.63M-0.2520MRKRMarker Therapeutics4.6605 of 5 stars$1.53+4.8%$13.17+760.6%-64.8%$16.52M$6.59M-1.1560News CoveragePositive NewsGap Up Related Companies and Tools Related Companies BioVie Competitors Cognition Therapeutics Competitors JATT Acquisition Competitors Q32 Bio Competitors Lipocine Competitors Cingulate Competitors Mannatech Competitors Gelteq Competitors Carisma Therapeutics Competitors Marker Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNOA) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNOA Stock Alerts